Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial

María Eugenia Toledo-Romani; Mayra García-Carmenate; Leslyhana Verdecia-Sánchez; Suzel Pérez-Rodríguez; Meybis Rodriguez-González; Carmen Valenzuela-Silva; Beatriz Paredes-Moreno; Belinda Sanchez-Ramirez; Raúl González-Mugica; Tays Hernández-Garcia; Ivette Orosa-Vázquez; Marianniz Díaz-Hernández; María Teresa Pérez-Guevara; Juliet Enriquez-Puertas; Enrique Noa-Romero; Ariel Palenzuela-Diaz; Gerardo Baro-Roman; Ivis Mendoza-Hernández; Yaima Muñoz; Yanet Gómez-Maceo; Bertha Leysi Santos-Vega; Sonsire Fernandez-Castillo; Yanet Climent-Ruiz; Laura Rodríguez-Noda; Darielys Santana-Mederos; Yanelda García-Vega; Guang Wu-Chen; Delaram Doroud; Alireza Biglari; Tammy Boggiano-Ayo; Yury Valdés-Balbín; Daniel García-Rivera; Dagmar García-Rivera; Vicente Vérez-Bencomo

bioRxiv (2022) - Comments
doi: 10.1101/2022.01.01.21268271

María Eugenia Toledo-Romani, Mayra García-Carmenate, Leslyhana Verdecia-Sánchez, Suzel Pérez-Rodríguez, Meybis Rodriguez-González, Carmen Valenzuela-Silva, Beatriz Paredes-Moreno, Belinda Sanchez-Ramirez, Raúl González-Mugica, Tays Hernández-Garcia, Ivette Orosa-Vázquez, Marianniz Díaz-Hernández, María Teresa Pérez-Guevara, Juliet Enriquez-Puertas, Enrique Noa-Romero, Ariel Palenzuela-Diaz, Gerardo Baro-Roman, Ivis Mendoza-Hernández, Yaima Muñoz, Yanet Gómez-Maceo